| Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study M Cavo, P Tosi, E Zamagni, C Cellini, P Tacchetti, F Patriarca, ... Journal of clinical oncology 25 (17), 2434-2441, 2007 | 493 | 2007 |
| Clinical outcome of extramedullary plasmacytoma P Galieni, M Cavo, A Pulsoni, G Avvisati, C Bigazzi, S Neri, U Caliceti, ... Haematologica 85 (1), 47-51, 2000 | 355 | 2000 |
| Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma G Martinelli, C Terragna, E Zamagni, S Ronconi, P Tosi, RM Lemoli, ... Journal of Clinical Oncology 18 (11), 2273-2281, 2000 | 215 | 2000 |
| Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma P Tosi, E Zamagni, C Cellini, S Ronconi, F Patriarca, F Ballerini, P Musto, ... Journal of the Peripheral Nervous System 7 (3), 209-209, 2002 | 146 | 2002 |
| Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma M Cavo, C Terragna, G Martinelli, S Ronconi, E Zamagni, P Tosi, ... Blood, The Journal of the American Society of Hematology 96 (1), 355-357, 2000 | 123 | 2000 |
| Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised … PL Zinzani, M Tani, A Pulsoni, M Gobbi, A Perotti, S De Luca, A Fabbri, ... The Lancet Oncology 9 (4), 352-358, 2008 | 100 | 2008 |
| Engraftment, clinical, and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose … RM Lemoli, G Martinelli, E Zamagni, MR Motta, S Rizzi, C Terragna, ... Blood, The Journal of the American Society of Hematology 95 (7), 2234-2239, 2000 | 99 | 2000 |
| Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure P Tosi, E Zamagni, S Ronconi, M Benni, MR Motta, S Rizzi, S Tura, ... Leukemia 14 (7), 1310-1313, 2000 | 87 | 2000 |
| Osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: a retrospective study T Ibrahim, F Barbanti, G Giorgio-Marrano, L Mercatali, S Ronconi, C Vicini, ... The Oncologist 13 (3), 330-336, 2008 | 86 | 2008 |
| Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone P Tosi, E Zamagni, D Cangini, P Tacchetti, F Di Raimondo, L Catalano, ... Blood 108 (12), 3951-3952, 2006 | 77 | 2006 |
| High-dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myeloma M Cavo, G Bandini, M Benni, A Gozzetti, S Ronconi, G Rosti, E Zamagni, ... Bone marrow transplantation 22 (1), 27-32, 1998 | 75 | 1998 |
| Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation P Tosi, S Ronconi, E Zamagni, C Cellini, T Grafone, D Cangini, SA Pileri, ... haematologica 86 (4), 409-413, 2001 | 72 | 2001 |
| Carfilzomib-lenalidomide-dexamethasone (KRd) induction-autologous transplant (ASCT)-Krd consolidation vs KRd 12 cycles vs carfilzomib-cyclophosphamide-dexamethasone (KCd … F Gay, C Cerrato, DR Scalabrini, M Galli, A Belotti, E Zamagni, A Ledda, ... Blood 132, 121, 2018 | 68 | 2018 |
| R-COMP 21 for frail elderly patients with aggressive B-cell non-Hodgkin lymphoma: a pilot study G Visani, F Ferrara, F Alesiani, S Ronconi, M Catarini, F D'adamo, ... Leukemia & lymphoma 49 (6), 1081-1086, 2008 | 58 | 2008 |
| Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long … P Tacchetti, L Pantani, F Patriarca, MT Petrucci, E Zamagni, L Dozza, ... The Lancet Haematology 7 (12), e861-e873, 2020 | 56 | 2020 |
| Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study M Cavo, M Benni, S Ronconi, M Fiacchini, A Gozzetti, E Zamagni, ... Haematologica 87 (9), 934-942, 2002 | 53 | 2002 |
| Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications A Zaccaria, N Testoni, AM Valenti, S Luatti, M Tonelli, G Marzocchi, ... Cancer genetics and cytogenetics 199 (2), 76-80, 2010 | 46 | 2010 |
| Efficacy and feasibility of dose/schedule-adjusted Rd-R vs. continuous Rd in elderly and intermediate-fit newly diagnosed multiple myeloma (NDMM) patients: RV-MM-PI-0752 phase … A Larocca, M Salvini, L De Paoli, N Cascavilla, G Benevolo, M Galli, ... Blood 132 (Supplement 1), 305-305, 2018 | 42 | 2018 |
| Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned … R Mina, P Musto, D Rota-Scalabrini, L Paris, B Gamberi, A Palmas, ... The Lancet Oncology 24 (1), 64-76, 2023 | 39 | 2023 |
| Bisphosphonates and Osteonecrosis of the Jaws: Incidence in a Homogeneous Series of Patients with Newly Diagnosed Multiple Myeloma Treated with Zoledronic Acid. P Tosi, E Zamagni, D Cangini, P Tacchetti, M Offidani, S Ronconi, ... Blood 106 (11), 3461, 2005 | 37 | 2005 |
